AMA Clinical Examples in Radiology - 2017 Issue 3 (Summer)
PET CT Brain Imaging Metabolic Evaluation
PET CT Brain Imaging Metabolic Evaluation CLINICAL HISTORY An 86-year-old female presents with progressive memory loss and personality change. After developing hallucinations and delusions, she was diagnosed clinically with Alzheimer's disease and was started on medication without noticeable clinical effect. Anatomic imaging demonstrated progressive volume loss and small vessel disease. The patient is referred to differentiate Alzheimer's disease from other forms of dementia. Dose: 11 mCi. Blood Glucose: 70 mg/dL. TECHNIQUE 78608 Following the intravenous injection of 18-fluoro-2-deoxyglucose (FDG) and a standard uptake period, a noncontrast computed tomography (CT) scan followed by a positron emission tomography (PET) scan of...
Subscribe or sign in to view the full article.
Article Overview
This article explains the coding and billing considerations for brain FDG PET metabolic evaluation in a dementia workup. It is aimed at coding professionals, radiology billing staff, and clinicians who need to understand the relevant CPT, HCPCS, and ICD-10-CM reporting context, as well as related coverage and documentation topics. The discussion also addresses how the imaging study is described, how the radiopharmaceutical is handled, and when additional modifier-related considerations may arise.
Why This Topic Matters
Accurate reporting for PET brain imaging affects claim integrity, coverage compliance, and proper separation of the imaging service from the radiopharmaceutical supply. The article is especially relevant when dementia evaluation, Medicare coverage, and related nuclear medicine billing questions intersect.
Article Sections
-
Clinical History
Summarizes the patient presentation and the clinical reason for the imaging study. It places the exam in the context of dementia evaluation and differential diagnosis.
-
Technique
Describes the imaging approach, tracer administration, and CT/PET acquisition details. It also notes the availability of quantitative analysis tools and other exam parameters.
-
Comparison Studies
Lists prior neuroimaging studies used for comparison. These references provide context for interpreting the current exam.
-
Findings
Summarizes the observed metabolic and anatomic imaging findings. The section focuses on the overall imaging pattern and its distribution.
-
Impression
Provides the radiologist’s overall interpretation of the exam. It states the general diagnostic direction suggested by the imaging pattern.
-
How to Code
Explains the coding framework for the imaging study, radiopharmaceutical supply reporting, and associated diagnosis coding. It also includes related documentation and payer considerations.
-
Discussion
Expands on coding, billing, and coverage topics for nuclear medicine and PET imaging. It also addresses related claims processing concepts and modifier use in a broader reimbursement context.
-
Coding tip
Highlights a practical billing point related to the professional component of the nuclear medicine study. The section gives general guidance on separate reporting conventions.
What You Will Learn
- The general purpose of FDG PET brain metabolic imaging in dementia evaluation
- How the article frames CPT, HCPCS Level II, and ICD-10-CM reporting for this type of study
- What kinds of billing and documentation issues are discussed for radiopharmaceuticals and PET/CT services
- How Medicare coverage and clinical-trial considerations are presented in the article
- What related modifier and claim-processing topics are discussed in the broader coding guidance
Who Should Read This
- Medical coders
- Radiology billing staff
- Nuclear medicine professionals
- Healthcare compliance staff
- Physicians ordering or interpreting dementia-related imaging
Codes Discussed
Modifiers Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com
